Free Trial
→ Why I went to Mount Rushmore (From Stansberry Research) (Ad)tc pixel
NASDAQ:GMAB

Genmab A/S Q3 2026 Earnings Date & Estimates

Genmab A/S logo
$37.07 +1.02 (+2.83%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$37.06 -0.01 (-0.03%)
As of 10/9/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genmab A/S is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 12:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
12:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Genmab A/S in Q3 2026

Genmab A/S is expected to post earnings of $0.37 per share on revenue of $1.20 billion. In the same quarter a year earlier Genmab A/S reported $0.65 per share on revenue of $1.02 billion. Genmab A/S last reported on August 6, 2026, posting $0.54 per share and beating the $0.37 consensus estimate. Genmab A/S has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.37
Expected Revenue
$1.20 billion
Prior-Year EPS
$0.65
Prior-Year Revenue
$1.02 billion
Expected EPS Growth
-43.1%
Expected Revenue Growth
+17.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.54 (Beat by +$0.17)
Last Quarter Revenue
$1.16 billion
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Genmab A/S Q3 2026 Earnings FAQ

Genmab A/S (NASDAQ:GMAB) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens.

Genmab A/S' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 12:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Genmab A/S to post earnings of $0.37 per share for Q3 2026.

The consensus revenue estimate for Genmab A/S is $1.20 billion for Q3 2026.

Genmab A/S Earnings Headlines

Genmab A/S Stock Earnings Estimates Lifted by HC Wainwright
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104840
Genmab To Issue Restricted Stock Units To Board Members As Renumeration
October 7 at 8:13 PM  |  rttnews.comhttps://www.rttnews.com/3697330/genmab-to-issue-restricted-stock-units-to-board-members-as-renumeration.aspx
Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.tc pixel
 |  Stansberry Research (Ad)
Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members
October 7 at 8:13 PM  |  marketscreener.comM
Genmab (CPSE:GMAB) Posts Two Strong Trial Readouts, Is The Valuation Now Too Hard To Ignore?
October 7 at 5:12 AM  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/genmab-cpse-gmab-posts-two-071643191.html
Genmab: Epkinly Shines In Phase 3 DLBCL Trial
October 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952323-genmab-epkinly-shines-in-phase-3-dlbcl-trial
See More Genmab A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genmab A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genmab A/S and other key companies, straight to your email.

About Genmab A/S

Genmab A/S (NASDAQ:GMAB) is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates. Its technologies have contributed to medicines such as DARZALEX (daratumumab) for multiple myeloma, Kesimpta (ofatumumab) for relapsing forms of multiple sclerosis, and Tivdak (tisotumab vedotin) for certain patients with cervical cancer. Genmab and AbbVie also developed EPKINLY (epcoritamab-bysp), a treatment for certain types of B-cell lymphoma. Commercial rights and responsibilities for these products vary among Genmab and its collaborators.

Founded in 1999, Genmab serves international markets through research, development and commercial partnerships spanning North America, Europe and other regions. The company maintains operations in Denmark, the United States and additional locations supporting its global development activities. Genmab is led by Dr. Jan van de Winkel, who serves as President and Chief Executive Officer and has been associated with the company’s scientific and operational development for many years.

View Genmab A/S Profile
Earnings Tools